Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on April 8, 2025, and filed on April 9, 2025. The filing details a share repurchase executed through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. It does not contain revenue, profit, cash flow, or margin data.
- Shares Purchased (April 8, 2025): 1,035,000 ordinary shares.
- Price Range: Lowest 1,326.00 GBp; Highest 1,360.50 GBp.
- Volume-Weighted Average Price (VWAP): 1,345.28 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Programme Progress: Since February 24, 2025, GSK has purchased 23,722,637 ordinary shares.
- Treasury Shares Held: 192,792,940 ordinary shares.
- Shares in Issue (excluding Treasury): 4,122,434,142.
- Total Voting Rights: 4,122,434,142.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the company. The total number of voting rights remains consistent with the number of shares in issue, as treasury shares do not carry voting rights. No other material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on February 24, 2025.
- Confirm the impact of the 192,792,940 treasury shares on earnings per share (EPS) calculations.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for the specific risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the completion status of the non-discretionary buyback agreement.